Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2023-08-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion statement regarding various company matters, including the half-year fundraising fund usage, nomination of board candidates, independent director remuneration, and external guarantees. It references the 2023 half-year period and discusses compliance with laws and regulations. The document does not contain full financial statements or detailed financial analysis but rather expresses independent opinions on specific governance and compliance issues. It is not a full interim report or annual report but a formal opinion related to governance and regulatory compliance matters. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory disclosure and independent opinion statement without substantive financial data or full report content.
2023-08-24 Chinese
2023年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 Half-Year Special Report on the Deposit and Use of Raised Funds" by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the amount of funds raised, their usage, storage, management, and investment projects related to the raised funds up to June 30, 2023. The document includes detailed financial figures about fundraising, usage, and cash management, but it is focused specifically on the use of raised funds rather than a full financial report or earnings release. It is a specialized report on fundraising usage and management, which aligns with the category of Capital/Financing Update (CAP). The document length is over 8,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the best classification is CAP.
2023-08-24 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and changes in accounting policies, which are typical contents of an interim or quarterly financial report. The document also references the full semi-annual report for comprehensive details, indicating this is a summary of a substantive financial report. The length is 3385 characters, which is relatively short, but the content includes actual financial figures and analysis, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-24 Chinese
独立董事候选人声明与承诺（王学恭）
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for Shenzhen Xinlitai Pharmaceutical Co., Ltd. It includes multiple attestations regarding the candidate's qualifications, independence, compliance with laws and regulations, and commitments to fulfill the duties of an independent director. There are no financial statements, earnings data, or report summaries. The content is focused on board/management information, specifically about a director candidate's qualifications and commitments. This fits the category of Board/Management Information (MANG), which covers announcements related to changes or nominations in the company's board of directors or senior management.
2023-08-24 Chinese
独立董事提名人声明与承诺（朱厚佳）
Board/Management Information Classification · 95% confidence The document is a detailed statement and commitment regarding the nomination of an independent director candidate for the company's board. It includes declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management information, specifically about director nomination and related compliance. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is sufficient and contains substantive content about management changes rather than a brief announcement or regulatory filing.
2023-08-24 Chinese
董事会提名委员会关于公司有关事项所发表的审查意见
Board/Management Information Classification · 100% confidence The document is a statement from the Board Nomination Committee regarding the qualifications and nomination of candidates for the company's board of directors. It references relevant laws and regulations about board member qualifications and confirms the nomination of specific individuals as board candidates. There is no financial data, no mention of an annual or interim report, no audit information, no voting results, and no other financial or regulatory filings. This document is clearly related to board/management information, specifically about board nominations and approvals. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short but contains substantive content about board nominations, not just an announcement or a report publication notice.
2023-08-24 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.